# A Study to Evaluate the Pharmacodynamic, Efficacy and Safety of SHR-1703 in Asthma Patients With Eosinophil Phenotype

> **NCT05522439** · PHASE2 · COMPLETED · sponsor: **Jiangsu HengRui Medicine Co., Ltd.** · enrollment: 85 (actual)

## Conditions studied

- Asthma With Eosinophilic Phenotype

## Interventions

- **DRUG:** SHR-1703
- **DRUG:** SHR-1703 Placebo

## Key facts

- **NCT ID:** NCT05522439
- **Lead sponsor:** Jiangsu HengRui Medicine Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-12-22
- **Primary completion:** 2024-09-12
- **Final completion:** 2024-09-12
- **Target enrollment:** 85 (ACTUAL)
- **Last updated:** 2025-05-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05522439

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05522439, "A Study to Evaluate the Pharmacodynamic, Efficacy and Safety of SHR-1703 in Asthma Patients With Eosinophil Phenotype". Retrieved via AI Analytics 2026-09-26 from https://api.ai-analytics.org/clinical/NCT05522439. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*